EUVIMEDEUVIMED entdecken
Klinische Studie (Phase I)

Cedirogant Population Pharmacokinetics and Pharmacodynamic Analyses of Interleukin‐17A Inhibition in Two Phase 1 Studies in Healthy Participants and Participants with Moderate to Severe Psoriasis

Corinna S Maier, Doerthe Eckert, F Stephen Laroux, Kinjal M Hew, Ahmed A Suleiman, Wei Liu, Mohamed-Eslam F Mohamed

Clinical Pharmacology in Drug Development · 2024

DOI: 10.1002/cpdd.1377 ↗

Kurz gefasst

Klinische Studie (Phase I) in der Zeitschrift Clinical Pharmacology in Drug Development, 2024. Verfasst von Corinna S Maier und 6 weiteren Autor:innen. Beteiligte Einrichtung: Clinical Pharmacology, AbbVie, Ludwigshafen, Germany. Hauptthemen laut MEDLINE: Healthy Volunteers, Interleukin-17, Models, Biological, Psoriasis. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 14 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Cedirogant (ABBV‐157) is an orally bioavailable inverse agonist of retinoic acid‐related orphan receptor gamma thymus. Data from 2 Phase 1 studies were used to characterize cedirogant pharmacokinetics and evaluate target engagement. Cedirogant plasma concentrations and ex vivo interleukin 17A (IL‐17A) concentrations from healthy participants and participants with moderate to severe psoriasis (PsO) were analyzed in a population pharmacokinetic and pharmacodynamic modeling framework to characterize cedirogant pharmacokinetics following single and multiple doses and assess ex vivo IL‐17A inhibition in relation to cedirogant exposure. Cedirogant population pharmacokinetics were best described by a 2‐compartment pharmacokinetic model with delayed absorption and an enzyme turnover compartment to describe cytochrome P450 3A autoinduction. The pharmacokinetics of cedirogant were comparable between healthy participants and participants with PsO. Cedirogant steady‐state average and maximum plasma concentrations were predicted to be 7.56 and 11.8 mg/L, respectively, for participants with PsO for the 375 mg once‐daily regimen on Day 14. The apparent clearance and apparent volume of distribution for cedirogant were estimated to be 24.5 L/day and 28.2 L, respectively. A direct maximum inhibition model adequately characterized the exposure‐response relationship of cedirogant and ex vivo IL‐17A inhibition, indicating no temporal delay between exposure and response with a saturable inhibition of IL‐17A. Model‐estimated half‐maximal inhibitory concentration and maximum inhibition values for cedirogant inhibition of ex vivo IL‐17A were 0.56 mg/L and 0.76, respectively. The established relationship between cedirogant exposure and biomarker effect supported dose selection for the Phase 2 dose‐ranging study in patients with PsO.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Healthy VolunteersInterleukin-17Models, BiologicalPsoriasisAdultFemaleHumansMaleMiddle AgedYoung AdultAdministration, OralDouble-Blind MethodSeverity of Illness Index

Stichwörter der Autor:innen

IL‐17Acedirogantpharmacodynamicspharmacokineticspsoriasis

Substanzen

IL17A protein, humanInterleukin-17

Autor:innen und Institutionen

  • Clinical Pharmacology, AbbVie, Ludwigshafen, Germany.
  • Precision Medicine Immunology, AbbVie Inc., Worcester, MA, USA.
  • Precision Medicine Immunology, AbbVie Inc., South San Francisco, CA, USA.
  • Clinical Pharmacology, AbbVie Inc., North Chicago, IL, USA.

Zitieren

APA

Maier, C. S., Eckert, D., Laroux, F. S., Hew, K. M., Suleiman, A. A., Liu, W., & Mohamed, M. F. (2024). Cedirogant Population Pharmacokinetics and Pharmacodynamic Analyses of Interleukin‐17A Inhibition in Two Phase 1 Studies in Healthy Participants and Participants with Moderate to Severe Psoriasis. Clinical Pharmacology in Drug Development. https://doi.org/10.1002/cpdd.1377

Vancouver

Maier CS, Eckert D, Laroux FS, Hew KM, Suleiman AA, Liu W, et al. Cedirogant Population Pharmacokinetics and Pharmacodynamic Analyses of Interleukin‐17A Inhibition in Two Phase 1 Studies in Healthy Participants and Participants with Moderate to Severe Psoriasis. Clinical Pharmacology in Drug Development. 2024. doi:10.1002/cpdd.1377

BibTeX
@article{Maier2024,
  author = {Maier, Corinna S and Eckert, Doerthe and Laroux, F Stephen and Hew, Kinjal M and Suleiman, Ahmed A and Liu, Wei and Mohamed, Mohamed-Eslam F},
  title = {Cedirogant Population Pharmacokinetics and Pharmacodynamic Analyses of Interleukin‐17A Inhibition in Two Phase 1 Studies in Healthy Participants and Participants with Moderate to Severe Psoriasis},
  journal = {Clinical Pharmacology in Drug Development},
  year = {2024},
  doi = {10.1002/cpdd.1377}
}
Kostenlos starten →